Separately, ValuEngine lowered Pieris Pharmaceuticals from a hold rating to a sell rating in a report on Friday, December 1st. One analyst has rated the stock with a sell rating and four have issued a buy rating to the stock. The company presently has a consensus rating of Buy and an average price target of $9.00.
Shares of Pieris Pharmaceuticals (NASDAQ PIRS) traded up $0.08 during trading on Wednesday, hitting $5.93. The stock had a trading volume of 492,900 shares, compared to its average volume of 614,524. Pieris Pharmaceuticals has a fifty-two week low of $1.38 and a fifty-two week high of $6.65.
In related news, major shareholder Orbimed Advisors Llc sold 147,635 shares of the business’s stock in a transaction that occurred on Monday, December 18th. The stock was sold at an average price of $5.70, for a total value of $841,519.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 4.05% of the stock is currently owned by insiders.
A number of institutional investors and hedge funds have recently bought and sold shares of PIRS. Voya Investment Management LLC acquired a new stake in Pieris Pharmaceuticals in the 2nd quarter worth approximately $100,000. Wells Fargo & Company MN acquired a new stake in Pieris Pharmaceuticals in the 3rd quarter worth approximately $105,000. State of Wisconsin Investment Board acquired a new stake in Pieris Pharmaceuticals in the 2nd quarter worth approximately $132,000. The Manufacturers Life Insurance Company lifted its holdings in Pieris Pharmaceuticals by 1,106.3% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 31,785 shares of the biotechnology company’s stock worth $161,000 after purchasing an additional 29,150 shares during the last quarter. Finally, Rhumbline Advisers acquired a new stake in Pieris Pharmaceuticals in the 2nd quarter worth approximately $184,000. Hedge funds and other institutional investors own 50.45% of the company’s stock.
About Pieris Pharmaceuticals
Pieris Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s pipeline includes immuno-oncology multi-specifics tailored for the tumor micro-environment, an inhaled Anticalin to treat uncontrolled asthma and a half-life-optimized Anticalin to treat anemia. Its Anticalins proteins are a class of low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins typically found in blood plasma and other bodily fluids.
Receive News & Ratings for Pieris Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pieris Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.